- Preparing For Appointments
- Contact Us
- Maps and Directions
- Clinical Trials
- Our Physicians
- Frequently Asked Questions
Events & Groups:
Join Us On Facebook.
Follow us on Twitter.
Clearview News Wire
Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Vaccine against deadly brain cancer shows promise
June 3, 2010
Last Updated: 2010-06-02 11:00:59 -0400 (Reuters Health)By Deena Beasley
LOS ANGELES (Reuters) - A small, early-stage trial of a therapeutic brain cancer vaccine developed by ImmunoCellular Therapeutics Ltd showed that nearly half the patients were alive without their cancer worsening 18 months after diagnosis, the company said on Wednesday.
The Phase 1 trial involved 16 patients with glioblastoma multiforme, the most common and deadly form of brain cancer.
They were treated with ICT-107, an experimental dendritic cell based cancer vaccine, following the standard care of surgery, radiation and chemotherapy.
"We are targeting specific antigens that are on cancer stem cells ... the only population of cells that can really propagate a tumor," said Dr. John Yu, director of surgical neuro-oncology at Cedars-Sinai Medical Center in Los Angeles and ImmunoCellular's chief scientific officer.
A year after diagnosis, all of the patients were alive. After two years, 80% were alive.
Historically, after a year with standard treatment, 61% of glioblastoma patients are alive, and 26.5% are alive after two years, according to the company.
In the ImmunoCellular trial, median overall survival had not yet been reached at the 26.4 months analysis point, with 12 out of 16 patients alive. Seven patients continued to live with no disease progression.
Side effects seen in the trial included fatigue and skin rash.
Dr. Yu said ImmunCellular is planning a mid-stage trial of the vaccine that would include between 30 and 50 patients.
Tweet
Other Articles:
- September 1, 2010
- More evidence hormone therapy can muddy mammograms
- August 31, 2010
- Prostate biopsy can cause urinary, erectile problems
- August 26, 2010
- Some men may get too many PSA tests: study
- August 24, 2010
- Ob/gyn group backs HPV vaccines for 11-12 year olds
- August 23, 2010
- Men with high CRP have higher risk of colon cancer
- August 20, 2010
- Developing nations to bear cancer brunt, unprepared
- August 19, 2010
- Race, ethnicity, other factors delay chemo after breast cancer surgery
- August 18, 2010
- Doctors discover tumor in Michael Douglas' throat
- August 16, 2010
- Personality not linked to cancer risk or prognosis
- August 13, 2010
- Cancer gets first TV comedy twist in "The Big C"
- August 9, 2010
- Avastin (bevacizumab) gives best lung cancer survival rate